Moderna's mRNA cancer vaccine actually worked in Phase 3

Moderna and Merck just announced their first Phase 3 success for a cancer vaccine — a personalized mRNA shot that trains the immune system to hunt down melanoma cells after surgery. It cut the risk of the cancer coming back by 44% compared to the old standard of care. The vaccine is made from the patient's own tumor DNA, so it's unique to each person.

The approach is a big deal because it flips cancer treatment on its head: instead of chemo or radiation attacking the body, it uses the immune system to do the hunting. This is the same mRNA platform Moderna used for the pandemic vaccine, but now it's being repurposed to fight a completely different kind of disease. Phase 3 data like this is what separates hype from real medicine.

Phase 3 is the last hurdle before FDA approval. Moderna and Merck plan to file for approval later this year. If it gets through, it could be the first mRNA cancer vaccine ever approved — and the proof point that this technology can treat serious diseases beyond infectious illness.

Why this matters for us: cancer hits hard in our communities and the people we love, and treatments that work are the difference between life and grief — this one was designed from the patient's own cells, which is something to hold onto.